Franklin Resources Inc. Has $22.38 Million Stock Position in uniQure N.V. $QURE

Franklin Resources Inc. lessened its holdings in uniQure N.V. (NASDAQ:QURE) by 19.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,605,515 shares of the biotechnology company’s stock after selling 382,173 shares during the period. Franklin Resources Inc. owned 2.93% of uniQure worth $22,381,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of QURE. Vestal Point Capital LP raised its holdings in uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after buying an additional 1,767,572 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of uniQure by 471.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after acquiring an additional 1,491,486 shares in the last quarter. Aberdeen Group plc lifted its holdings in uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company’s stock worth $23,485,000 after purchasing an additional 706,216 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in uniQure in the 1st quarter worth approximately $4,240,000. Finally, Russell Investments Group Ltd. bought a new stake in uniQure during the first quarter worth approximately $3,218,000. 78.83% of the stock is currently owned by institutional investors.

Insider Transactions at uniQure

In related news, Director Jack Kaye sold 38,810 shares of the company’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the completion of the transaction, the director directly owned 20,439 shares in the company, valued at approximately $620,119.26. This represents a 65.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert Gut sold 31,434 shares of uniQure stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84. Following the sale, the director owned 40,145 shares in the company, valued at $1,094,352.70. This represents a 43.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 314,560 shares of company stock valued at $12,362,568. Company insiders own 4.79% of the company’s stock.

uniQure Stock Performance

NASDAQ:QURE opened at $27.63 on Friday. The firm’s 50-day moving average is $45.50 and its 200-day moving average is $25.62. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -7.05 and a beta of 0.59. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. uniQure N.V. has a 52-week low of $5.86 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last released its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. Equities research analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. HC Wainwright reduced their price objective on shares of uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, October 8th. Guggenheim upped their price target on shares of uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Cantor Fitzgerald lifted their price objective on uniQure from $47.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Finally, Mizuho boosted their price objective on uniQure from $30.00 to $60.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $64.42.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.